NovAlix today announces that it has entered into a multi-year research services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.
Under the terms, NovAliX scientists will provide distant as well on-site chemistry support, optimally exploiting strong organic synthetic expertise and unique biophysical capabilities, to accelerate the drug discovery process. In addition the operational excellence of NovAliX allows to explore a complete new model by which the respective scientists work side by side for greater efficiency and scientific exchange and therefore promoting the concept of Open Innovation.
Stephan Jenn, president of NovAliX, said "he welcomes this significant chemistry discovery deal that acknowledges the quality of our science, technologies and organization".
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis